DelveInsight has launched a new report on “Venous Thromboembolism – Market Insights, Epidemiology, and Market Forecast-2030”.
DelveInsight’s “Venous Thromboembolism – Market Insights, Epidemiology, and Market Forecast-2030″ report delivers an in-depth understanding of the Venous Thromboembolism, historical and forecasted epidemiology as well as the Venous Thromboembolism market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Some of the key facts of the Venous Thromboembolism Market Report:
The Centers for Disease Control and Prevention (CDC) estimated that:
Over a 3-year period (2007–2009), there was an estimated annual average of 547,596 hospitalizations in which VTE was diagnosed, for patients aged 18 years or older.
Over the same period, for the same age group, an estimated average of 348,558 and 277,549 hospitalizations for DVT and PE were diagnosed annually. Among these patients, an estimated average of 78,511 hospitalizations for both DVT and PE were diagnosed annually.
Key benefits of the report:
Venous Thromboembolism market report covers a descriptive overview and comprehensive insight of the Venous Thromboembolism Epidemiology and Venous Thromboembolism market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
The Venous Thromboembolism market report provides insights on the current and emerging therapies.
Venous Thromboembolism market report provides a global historical and forecasted market covering drug outreach in 7MM.
The Venous Thromboembolism market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Venous Thromboembolism market.
Venous Thromboembolism Overview
Venous Thromboembolism (VTE) is a disorder that includes Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE). A deep vein thrombosis (DVT) occurs when a blood clot forms in a deep vein, usually in the lower leg, thigh, or pelvis. A deep vein thrombosis may occur if the flow of blood slows down in the body’s deep veins. A pulmonary embolism (PE) occurs when a clot breaks loose and travels through the bloodstream to the lungs. The leading risk factor for VTE is long-term hospitalization, and the risk is high in patients with respiratory and circulatory system complications. The most common types of surgery associated with VTE are orthopaedic surgeries, especially knee and hip replacements.
Venous Thromboembolism Market
The dynamics of the Venous Thromboembolism market are anticipated to change in the coming years owing to the expected launch of emerging therapies such as Bayer Pharmaceuticals, Bristol-Myers Squibb/Janssen Pharmaceuticals, Quercis Pharma, Ono Pharmaceuticals, Verseon Corporation, Bayer Pharmaceuticals/Ionis, and others during the forecasted period 2018-2030.
Venous Thromboembolism Pipeline Therapies and Key Companies
Osocimab (BAY 1213790): Bayer Pharmaceuticals
Milvexian (JNJ-70033093; BMS-986177): Bristol-Myers Squibb/Janssen Pharmaceuticals
Isoquercetin: Quercis Pharma
ONO-7684: Ono Pharmaceuticals
VE-1902: Verseon Corporation
IONIS-FXI-LRx (BAY2976217): Bayer Pharmaceuticals/Ionis
Table of Contents
1. Report Introduction
2. Executive Summary
3. SWOT analysis
4. Venous Thromboembolism Patient Share (%) Overview at a Glance
5. Venous Thromboembolism Market Overview at a Glance
6. Venous Thromboembolism Disease Background and Overview
7. Venous Thromboembolism Epidemiology and Patient Population
8. Country-Specific Patient Population of Venous Thromboembolism
9. Venous Thromboembolism Current Treatment and Medical Practices
10. Unmet Needs
11. Venous Thromboembolism Emerging Therapies
12. Venous Thromboembolism Market Outlook
13. Country-Wise Venous Thromboembolism Market Analysis (2018–2030)
14. Market Access and Reimbursement of Therapies
15. Market drivers
16. Market barriers
18. Venous Thromboembolism Report Methodology
19. DelveInsight Capabilities
21. About DelveInsight
“Venous Thromboembolism Pipeline Insight, 2021” report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Venous Thromboembolism market. A detailed picture of the Venous Thromboembolism pipeline landscape is provided, which includes the disease overview and Venous Thromboembolism treatment guidelines.
DelveInsight’s ‘Venous Thromboembolism Epidemiology Forecast to 2030’ report delivers an in-depth understanding of the disease, historical and forecasted Venous Thromboembolism epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Address:304 S. Jones Blvd #2432
City: Las Vegas
Country: United States